On May 25, 2022, MiMedx Group, Inc. announced that a proxy advisory firm Institutional Shareholder Services (ISS) has recommended that shareholders vote for all of the Company's proposals including for both of the Company director nominees James L. Bierman and Phyllis Gardner, on the Company's proxy card at its 2022 annual meeting of shareholders scheduled for June 7, 2022, which would be held in virtual format at www.cesonlineservices.com/mdxg22_vm.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.51 USD | +2.36% | +4.49% | -25.77% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.77% | 961M | |
-19.12% | 131M | |
+10.84% | 63.05M | |
-15.49% | 61.84M | |
+13.04% | 61.14M | |
-0.60% | 50.36M |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.
- Institutional Shareholder Services Supports MiMedx Group